8-K
Theravance Biopharma, Inc. (TBPH)
View as plain text
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): December 16, 2021
THERAVANCE BIOPHARMA, INC.
(Exact Name of Registrant as Specified in its Charter)
| Cayman Islands | 001-36033 | 98-1226628 |
|---|---|---|
| (State or Other Jurisdiction of | (Commission File Number) | (I.R.S.<br>Employer Identification |
| Incorporation) | Number) |
PO Box 309
Ugland House, South Church Street
George Town, Grand Cayman, Cayman Islands KY1-1104
(650) 808-6000
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written<br>communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ¨ | Soliciting<br>material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ¨ | Pre-commencement<br>communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ¨ | Pre-commencement<br>communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br> Symbol(s) | Name of each exchange<br> <br><br>on which registered |
|---|---|---|
| Ordinary Share $0.00001 Par Value | TBPH | NASDAQ Global<br> Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
The information in this Current Report is being furnished and shallnot be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwisesubject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registrationstatement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific referencein such filing.
Theravance Biopharma, Inc. will hold its 2022 Annual General Meeting on April 26, 2022.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| THERAVANCE BIOPHARMA, INC. | ||
|---|---|---|
| Date: December 16, 2021 | By: | /s/ Brett Grimaud |
| Brett Grimaud | ||
| Vice President and General Counsel |